Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 4
1991 3
1992 5
1993 4
1994 5
1995 3
1999 3
2009 2
2010 1
2011 2
2012 1
2013 3
2014 2
2015 3
2016 4
2017 4
2018 2
2019 2
2020 2
2021 1
2022 4
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

55 results

Results by year

Filters applied: . Clear all
Page 1
Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial.
Conroy T, Bosset JF, Etienne PL, Rio E, François É, Mesgouez-Nebout N, Vendrely V, Artignan X, Bouché O, Gargot D, Boige V, Bonichon-Lamichhane N, Louvet C, Morand C, de la Fouchardière C, Lamfichekh N, Juzyna B, Jouffroy-Zeller C, Rullier E, Marchal F, Gourgou S, Castan F, Borg C; Unicancer Gastrointestinal Group and Partenariat de Recherche en Oncologie Digestive (PRODIGE) Group. Conroy T, et al. Among authors: gargot d. Lancet Oncol. 2021 May;22(5):702-715. doi: 10.1016/S1470-2045(21)00079-6. Epub 2021 Apr 13. Lancet Oncol. 2021. PMID: 33862000 Clinical Trial.
Comparison of short course radiotherapy with chemoradiotherapy for locally advanced rectal cancers in the elderly: A multicentre, randomised, non-blinded, phase 3 trial.
François E, De Bari B, Ronchin P, Nouhaud E, Martel-Lafay I, Artru P, Clavere P, Vendrely V, Boige V, Gargot D, Lemanski C, De Sousa Carvalho N, Gal J, Pernot M, Magné N. François E, et al. Among authors: gargot d. Eur J Cancer. 2023 Feb;180:62-70. doi: 10.1016/j.ejca.2022.11.020. Epub 2022 Nov 28. Eur J Cancer. 2023. PMID: 36535196 Clinical Trial.
The PRSS3P2 and TRY7 deletion copy number variant modifies risk for chronic pancreatitis.
Masson E, Ewers M, Paliwal S, Kume K, Scotet V, Cooper DN, Rebours V, Buscail L, Rouault K; GREPAN (Genetic REsearch on PANcreatitis) Study Group; Abrantes A, Aguilera Munoz L, Albouys J, Alric L, Amiot X, Archambeaud I, Audiau S, Bastide L, Baudon J, Bellaiche G, Bellon S, Bertrand V, Bideau K, Billiemaz K, Billioud C, Bonnefoy S, Borderon C, Bournet B, Breton E, Brugel M, Buscail L, Cadiot G, Camus M, Carpentier-Pourquier M, Chamouard P, Chaput U, Chen JM, Cholet F, Ciocan DM, Clavel C, Coffin B, Coimet-Berger L, Cosconea S, Creveaux I, Culetto A, Daboussi O, De Mestier L, Degand T, D'engremont C, Denis B, Dermine S, Desgrippes, Drouet D'Aubigny A, Enaud R, Fabre A, Férec C, Gargot D, Gelsi E, Gentilcore E, Gincul R, Ginglinger-Favre E, Giovannini M, Gomercic C, Gondran H, Grainville T, Grandval P, Grasset D, Grimaldi S, Grimbert S, Hagege H, Heissat S, Hentic O, Herber-Mayne A, Hervouet M, Hoibian S, Jacques J, Jais B, Kaassis M, Koch S, Lacaze E, Lacroute J, Lamireau T, Laurent L, Le Guillou X, Le Rhun M, Leblanc S, Levy P, Lievre A, Lorenzo D, Maire F, Marcel K, Masson E, Mauillon J, Morgant S, Moussata D, Muller N, Nambot S, Napoleon B, Olivier A, Pagenault M, Pelleti… See abstract for full author list ➔ Masson E, et al. Among authors: gargot d. Pancreatology. 2023 Jan;23(1):48-56. doi: 10.1016/j.pan.2022.11.013. Epub 2022 Dec 5. Pancreatology. 2023. PMID: 36517351
[Moxisylyte-induced cytolytic hepatitis?].
Lévy-Bruhl A, Germanaud J, Gargot D, Legoux JL. Lévy-Bruhl A, et al. Among authors: gargot d. Gastroenterol Clin Biol. 1991;15(12):979. Gastroenterol Clin Biol. 1991. PMID: 1723707 French. No abstract available.
How are patients' preferences for anti-TNF influenced by quality of life? A discrete choice experiment in Crohn's disease patients.
Brunet-Houdard S, Monmousseau F, Berthon G, Des Garets V, Laharie D, Picon L, Fotsing G, Gargot D, Charpentier C, Buisson A, Trang-Poisson C, Dib N, Rusch E, Aubourg A; COQC-PIT Study Group. Brunet-Houdard S, et al. Among authors: gargot d. Scand J Gastroenterol. 2022 Nov;57(11):1312-1320. doi: 10.1080/00365521.2022.2085057. Epub 2022 Jun 18. Scand J Gastroenterol. 2022. PMID: 35722732
Predictors of each quality of life dimension in Crohn's disease patients initiating an anti-TNF treatment: differentiated effects of patient-, disease-, and treatment-related characteristics.
Monmousseau F, Mulot L, Rusch E, Picon L, Laharie D, Fotsing G, Gargot D, Charpentier C, Buisson A, Trang-Poisson C, Dib N, DES Garets V, Brunet-Houdard S, Aubourg A; COQC-PIT Study Group. Monmousseau F, et al. Among authors: gargot d. Scand J Gastroenterol. 2022 May;57(5):566-573. doi: 10.1080/00365521.2021.2025419. Epub 2022 Feb 21. Scand J Gastroenterol. 2022. PMID: 35188859
[Liver steatosis. II: Microvesicular steatosis].
Causse X, Gargot D, Michenet P. Causse X, et al. Among authors: gargot d. Gastroenterol Clin Biol. 1995 Jan;19(1):66-75. Gastroenterol Clin Biol. 1995. PMID: 7720993 Review. French. No abstract available.
55 results